When federal regulators considered whether to approve the new cancer drug Adcetris in 2011, five patients showed up at an advisory committee meeting to talk about the need for the drug.
All of them had their travel expenses paid for by Seattle Genetics, the company that makes the drug. They told compelling stories and when the final vote was taken, it was a slam dunk.
Experts on the committee voted 10-0 to recommend approval.
Read Full Article »